University of Maryland School of Pharmacy faculty members released a new software application called Pumas—a platform designed to assist strategic decision-making across the fields of drug development and individualized patient care.
Who Developed Pumas-AI?
A company established by two University of Maryland professor, Vijay Ivaturi, Ph.D., and Joga Gobburu. Known as “Pharmaceutical Modeling and Simulation, or Pumas, they was developed through a partnership with experts at Julia Computing Research, and software development efforts were led by Christopher Rackauckas, Ph.D., Senior Research Analyst, with input from independent contributor Joakim Nyberg, Ph.D., Uppsala Sweden, reported the Baltimore Business Journal.
What is Pumas-AI
A comprehensive platform based on the open-source Julia programming language, it contains multiple modules designed to meet the needs of the analysts in the pharmaceutical industry, while also working to advance therapeutic innovation in the clinic setting.
The launch of Pumas comes before JuliaCon 2019, being held at the University of Maryland, Baltimore.
Pumas, a comprehensive platform based on the Julia programming language, contains multiple modules designed to meet the needs of analysts in the pharmaceutical industry, while also working to advance therapeutic innovation in the clinic setting. Users of the Julia programming language are holding a conference in Baltimore from July 23rd through 26th.
“The success rate for pharmaceutical innovations is approximately two percent,” says Gobburu, who also serves as executive director of the Center for Translational Medicine (CTM) at the School of Pharmacy. “Pumas software is tailored to revolutionize big data analytics in health care, unlike those tools used in other fields.
“By combining the extensive healthcare knowledge of our faculty and staff with the scientific computing experts at Julia Computing, we have developed a tool that will not only benefit business leaders working in the pharmaceutical industry, but also those who are caring for patients on the front line of healthcare delivery.”